⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

January 27, 2021Seminars in Arthritis and RheumatismOpen Access

The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review

Robert T. Keenan John K. Botson Karim R. Masri Lissa Padnick‐Silver Brian LaMoreaux John A. Albert Michael H. Pillinger

View Full Paper

Ask AI

Bookmark

Share

Abstract

Published reports suggest that immunomodulation co-therapy has the potential to markedly improve pegloticase responder rates in patients with uncontrolled gout.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Keenan et al. (2021) studied this question.

synapsesocial.com/papers/69d75b5cf182769aa8b8a963 https://doi.org/10.1016/j.semarthrit.2021.01.005

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Uricase protein sequences: conserved during vertebrate evolution but absent in humansOriginal Research · 1988 · 66 citations
2Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agentsOriginal Research · 2012 · 587 citations
3Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol–conjugated uricase) in patients with treatment‐failure gout: Results of a phase II randomized studyEarly-Phase Clinical Trial · 2008 · 181 citations
4Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional TreatmentBlinded Clinical Trial · 2011 · 526 citations
5Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipientsEarly-Phase Clinical Trial · 2014 · 266 citations

More related papers

Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase2005
Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy2014
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout2014

More from Seminars in Arthritis and Rheumatism

Incidence and characteristics of cytokine release syndrome in patients with systemic sclerosis undergoing autologous haematopoietic stem cell transplantationThu,
All-cause emergency department visits and hospitalizations in persons with rheumatoid arthritis: A systematic reviewSun,